targeted immune system activation

ISA Pharmaceuticals Status on Novel Coronavirus (COVID-19)

The recent events and rise of the COVID-19 virus on a global scale have brought challenges to us in ways that were unimaginable at the beginning of the year. We have been following the guidance published by the governments in the countries that we operate in to keep our employees safe, whilst ensuring that we continue to develop targeted, rationally designed immunotherapeutics for the treatment of cancer and persistent virus infections.

As always, we remain focused on supporting the wellbeing and safety of our staff.

Thank you and best wishes through this period.

introduction to ISA

ISA Pharmaceuticals develops targeted, rationally designed immunotherapeutics for the treatment of cancer and persistent virus infections.

feature

ISA101b and cemiplimab (Libtayo®) study in patients with platinum refractory HPV16 positive oropharyngeal cancer (OPC). Read more.